Effect of Radioiodine Treatment on Quality of Life in Patients with Subclinical Hyperthyroidism: A Prospective Controlled Study

Abstract

Radioiodine treatment (RIT) has a high success rate in both the treatment of hyperthyroidism and improving the quality of life (QoL) of symptomatic patients. In asymptomatic patients with subclinical hyperthyroidism thyroid related QoL outcomes are less well known.

Methods Study aim was to evaluate thyroid-related QoL in patients with subclinical hyperthyroidism mostly due to toxic nodular goitre undergoing RIT, compared to a control group of euthyroid subjects. Study design was monocentric, prospective, controlled. Fifty control subjects were enrolled and 51 RIT patients. Most subjects were examined at least twice at an interval of 6 months, with visits immediately before and 6 months after treatment in the RIT group. QoL was estimated with the ThyPRO questionnaire, using its composite scale as primary outcome. Treatment effect was the mean adjusted difference (MAD) between groups over time, using repeated? measures mixed? effects models.

Results TSH concentrations were lower in the RIT group prior to treatment and recovered thereafter slightly above the level of the control group. Correspondingly, QoL improved significantly after 6 months from a worse level in the RIT group, compared to controls (MAD –10.3 [95% CI –14.9, –5.7], p<0.001). QoL improvements were strong for general items, but less pronounced for the hyperthyroid domain. Compared to controls, thyroid volume, thyroid functional capacity (SPINA-GT) and deiodinase activity (SPINA-GD) were significantly reduced in the RIT group.

Conclusion Patients with subclinical hyperthyroidism improve both biochemically and in their QoL after RIT, compared to controls. QoL assessment should have a wider role in clinical practice to complement biochemical tests and help with treatment decisions.

Keywords

subclinical hyperthyroidism - quality of live - radioiodine treatment - prospective study

Publication History

Received: 16 September 2023

Accepted after revision: 08 January 2024

Article published online:
23 January 2024

• References

• 1 Taylor PN, Albrecht D, Scholz A. et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 2018; 14: 301-316 DOI: 10.1038/nrendo.2018.18. (PMID: 29569622)
• 2 Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010; 6: 431-443 DOI: 10.1038/nrendo.2010.105. (PMID: 20585347)
• 3 Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: Aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol 2023; 11: 282-298 DOI: 10.1016/S2213-8587(23)00005-0. (PMID: 36848916)
• 4 Sjölin G, Holmberg M, Törring O. et al. The long-term outcome of treatment for Graves’ hyperthyroidism. Thyroid 2019; 29: 1545-1557 DOI: 10.1089/thy.2019.0085. (PMID: 31482765)
• 5 Heeringa J, Hoogendoorn EH, Van Der Deure WM. et al. High-normal thyroid function and risk of atrial fibrillation: The Rotterdam study. Arch Int Med 2008; 168: 2219-2224 DOI: 10.1001/archinte.168.20.2219. (PMID: 19001198)
• 6 Chaker L, Heeringa J, Dehghan A. et al. Normal thyroid function and the risk of atrial fibrillation: The Rotterdam study. J Clin Endocrinol Metab 2015; 100: 3718-3724 DOI: 10.1210/jc.2015-2480. (PMID: 26262438)
• 7 Baumgartner C, Da Costa BR, Collet TH. et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation 2017; 136: 2100-2116
• 8 Müller P, Leow MK, Dietrich JW. Minor perturbations of thyroid homeostasis and major cardiovascular endpoints-physiological mechanisms and clinical evidence. Front Cardiovasc Med 2022; 9: 942971 DOI: 10.3389/fcvm.2022.942971. (PMID: 36046184)
• 9 Phowira J, Coffey KL, Bartholomew PH. et al. Radioactive iodine for the treatment of subclinical thyrotoxicosis GRADE 1 and 2: Outcome of up to 18-year follow up. Front Endocrinol (Lausanne) 2022; 13: 843857 DOI: 10.3389/fendo.2022.843857. (PMID: 35370990)
• 10 Stadje R, Dornieden K, Baum E. et al. The differential diagnosis of tiredness: A systematic review. BMC Fam Pract 2016; 17: 147 DOI: 10.1186/s12875-016-0545-5. (PMID: 27765009)
• 11 Larisch R, Schulte S, Hildenbrand G. et al. The role of thyroid hormones in anxiety and depression (abstract). Nuklearmedizin 2015; 53: V162
• 12 Hoermann R, Midgley JEM, Larisch R. et al. Relational stability of thyroid hormones in euthyroid subjects and patients with autoimmune thyroid disease. Eur Thyroid J 2016; 5: 171-179
• 13 Hedman C, Djärv T, Strang P. et al. Effect of thyroid-related symptoms on long-term quality of life in patients with differentiated thyroid carcinoma: A population-based study in Sweden. Thyroid 2017; 27: 1034-1042
• 14 Wekking EM, Appelhof BC, Fliers E. et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005; 153: 747-753 DOI: 10.1530/eje.1.02025. (PMID: 16322379)
• 15 Larisch R, Midgley JEM, Dietrich JW. et al. Symptomatic relief is related to serum free triiodothyronine concentrations during follow-up in levothyroxine-treated patients with differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 2018; 126: 546-552
• 16 Fitzgerald SP, Bean NG, Falhammar H. et al. Clinical parameters are more likely to be associated with thyroid hormone levels than with thyrotropin levels: A systematic review and meta-analysis. Thyroid 2020; 30: 1695-1709
• 17 Hoermann R, Midgley JEM, Larisch R. et al. Is pituitary TSH an adequate measure of thyroid hormone-controlled homoeostasis during thyroxine treatment. Eur J Endocrinol 2013; 168: 271-280 DOI: 10.1530/EJE-12-0819.
• 18 Hoermann R, Pekker MJ, Midgley JEM. et al. The role of supporting and disruptive mechanisms of FT3 homeostasis in regulating the hypothalamic-pituitary-thyroid axis. Ther Adv Endocrinol Metab 2023; 14 DOI: 10.1177/20420188231158163. (PMID: 36936128)
• 19 Watt T, Cramon P, Hegedüs L. et al. The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. J Clin Endocrinol Metab 2014; 99: 3708-3717 DOI: 10.1210/jc.2014-1322. (PMID: 25004246)
• 20 Cramon PK, Bjorner JB, Groenvold M. et al. Implementation of thyroid-related patient-reported outcomes in routine clinical practice. Front Endocrinol (Lausanne) 2022; 13: 1000682 DOI: 10.3389/fendo.2022.1000682. (PMID: 36246917)
• 21 Watt T, Hegedüs L, Groenvold M. et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, thypro. Eur J Endocrinol 2010; 162: 161-167 DOI: 10.1530/EJE-09-0521. (PMID: 19797502)
• 22 Tabriz N, Gloy K, Schantzen A. et al. Validity and reliability of the German version of the shortened thyroid-specific quality of life questionnaire (ThyPRO-39de). Endocr Connect 2021; 10: 1065-1072 DOI: 10.1530/EC-21-0114. (PMID: 34355699)
• 23 Chan EKH, Edwards TC, Haywood K. et al. Implementing patient-reported outcome measures in clinical practice: A companion guide to the isoqol user’s guide. Quality of Life Research 2019; 28: 621-627 DOI: 10.1007/s11136-018-2048-4. (PMID: 30448911)
• 24 Watt T, Bjorner JB, Groenvold M. et al. Development of a short version of the thyroid-related patient-reported outcome ThyPRO. Thyroid 2015; 25: 1069-1079 DOI: 10.1089/thy.2015.0209. (PMID: 26214034)
• 25 Cramon P, Bonnema SJ, Bjorner JB. et al. Quality of life in patients with benign nontoxic goiter: Impact of disease and treatment response, and comparison with the general population. Thyroid 2015; 25: 284-291
• 26 Larisch R, Giacobino A, Eckl WA. et al. Reference range for thyrotropin. Post hoc assessment. Nuklearmedizin 2015; 54: 112-117 DOI: 10.3413/Nukmed-0671-14-06. (PMID: 25567792)
• 27 Dietrich JW, Landgrafe-Mende G, Wiora E. et al. Calculated parameters of thyroid homeostasis: Emerging tools for differential diagnosis and clinical research. Front Endocrinol (Lausanne) 2016; 7: 57 DOI: 10.3389/fendo.2016.00057. (PMID: 27375554)
• 28 Hoermann R, Midgley JEM, Larisch R. et al. Relational stability in the expression of normality, variation, and control of thyroid function. Front Endocrinol (Lausanne) 2016; 7: 142 DOI: 10.3389/fendo.2016.00142. (PMID: 27872610)
• 29 Dietlein M, Grünwald F, Schmidt M. et al. Radioiodine therapy for benign thyroid diseases (version 5). Nuklearmedizin 2016; 55: 213-220 DOI: 10.3413/Nukmed-0823-16-04. (PMID: 27922153)
• 30 Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes; practical considerations in therapy and protection. Am J Roentgenol Radium Ther 1948; 59: 260-281 (PMID: 18905884)
• 31 Bates D, Kliegl R, Vasishth S. et al. Parsimonious mixed models. arXivorg 2015; 1-27
• 32 Allison DB, Brown AW, George BJ. et al. Reproducibility: A tragedy of errors. Nature 2016; 530: 27-29 DOI: 10.1038/530027a. (PMID: 26842041)
• 33 De Rosario-Martinez H. Phia: Post-hoc interaction analysis. R package version 0.2–1. 2015 https://cran.r-project.org/package=phia
• 34 R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2023; ISBN 3–900051–07–0. https://www.R-project.org/
• 35 Bates D, Mächler M, Bolker B. et al. Fitting linear mixed-effects models using lme4. J Stat Softw 2015; 67: 1-48
• 36 Jonklaas J, Bianco AC, Bauer AJ. et al. Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 2014; 24: 1670-1751 DOI: 10.1089/thy.2014.0028. (PMID: 25266247)
• 37 Midgley JEM, Toft AD, Larisch R. et al. Time for a reassessment of the treatment of hypothyroidism. BMC Endocr Disord 2019; 19: 37 DOI: 10.1186/s12902-019-0365-4. (PMID: 30999905)
• 38 Fitzgerald SP, Bean NG, Hennessey JV. et al. Thyroid testing paradigm switch from thyrotropin to thyroid hormones-future directions and opportunities in clinical medicine and research. Endocrine 2021; 74: 285-289
• 39 Poertl S, Kirner J, Saller B. et al. T3-release from autonomously functioning thyroid nodules in vitro. Exp Clin Endocrinol Diabetes 1998; 106: 489-493
• 40 Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13: 596-611 DOI: 10.1210/edrv-13-3-596. (PMID: 1425489)
• 41 Andersen S, Pedersen KM, Bruun NH. et al. Narrow individual variations in serum T4 and T3 in normal subjects: A clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002; 87: 1068-1072 DOI: 10.1210/jcem.87.3.8165. (PMID: 11889165)
• 42 Hoermann R, Midgley JEM, Larisch R. et al. Individualised requirements for optimum treatment of hypothyroidism: Complex needs, limited options. Drugs Context 2019; 8: 212597 DOI: 10.7573/dic.212597. (PMID: 31516533)
• 43 Hoermann R, Midgley JEM, Larisch R. et al. Functional and symptomatic individuality in the response to levothyroxine treatment. Front Endocrinol (Lausanne) 2019; 10: 664 DOI: 10.3389/fendo.2019.00664. (PMID: 31616383)
• 44 Brown VA. An introduction to linear mixed-effects modeling in r. Adv Meth Pract Psychol Sci 2021; 4 (01) DOI: 10.1177/2515245920960351.
• 45 Hoermann R, Pekker M, Midgley JE. et al. Principles of endocrine regulation: Reconciling tensions between robustness in performance and adaptation to change. Front Endocrinol 2022; 13: 825107
• 46 Wong CK, Lang BH, Lam CL. A systematic review of quality of thyroid-specific health-related quality-of-life instruments recommends ThyPRO for patients with benign thyroid diseases. J Clin Epidemiol 2016; 78: 63-72 DOI: 10.1016/j.jclinepi.2016.03.006. (PMID: 27020087)
• 47 Stott DJ, Rodondi N, Kearney PM. et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 2017; 376: 2534-2544
• 48 Heald AH, Premawardhana L, Taylor P. et al. Is there a role for natural desiccated thyroid in the treatment of levothyroxine unresponsive hypothyroidism? Results from a consecutive case series. Int J Clin Pract 2021; 75: e14967
• 49 Törring O, Watt T, Sjölin G. et al. Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves’ hyperthyroidism: A long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey. Thyroid 2019; 29: 322-331 DOI: 10.1089/thy.2018.0315. (PMID: 30667296)